Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | FABP7 | O15540 | 1/20 | 0.45 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
| ▸ | MDM4 | O15151 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19378090 | 0.89 | CASP3 (0.48) | CASP3KMT2AFABP7FABP5EPHX2 | |
| SCHEMBL17513345 | 0.89 | CASP3 (0.48) | CASP3KMT2AFABP7FABP5EPHX2 | |
| SCHEMBL3135960 | 0.87 | CASP3 (0.51) | CASP3KMT2AEPHX2MDM4TP53 | |
| SCHEMBL15248847 | 0.85 | CASP3 (0.52) | CASP3KMT2AEPHX2MDM4TP53 | |
| SCHEMBL3039215 | 0.84 | CASP3 (0.57) | CASP3KMT2AEPHX2CTSKMDM4 | |
| SCHEMBL8355967 | 0.84 | CASP3 (0.57) | CASP3KMT2AEPHX2CTSKMDM4 | |
| SCHEMBL29664082 | 0.84 | CASP3 (0.57) | CASP3KMT2AEPHX2CTSKMDM4 | |
| SCHEMBL13323320 | 0.84 | CASP3 (0.57) | CASP3KMT2AEPHX2CTSKMDM4 | |
| SCHEMBL3132278 | 0.83 | KMT2A (0.46) | CASP3KMT2AFABP7FABP5EPHX2 | |
| SCHEMBL120599 | 0.83 | MDM4 (0.54) | CASP3KMT2AFABP7FABP5MDM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1491537-B1 | HYDROXYMORPHOLINONE DERIVATIVE AND MEDICINAL USE THEREOF | SENJU PHARMA CO (JP) | 2010-07-07 | — | — | EP | disclosed |
| US-7223755-B2 | Hydroxymorpholinone derivative and medicinal use thereof | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2007-05-29 | — | — | US | disclosed |
| US-20050176704-A1 | Hydroxymorpholinone derivative and medicinal use thereof | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176704-A1 | Hydroxymorpholinone derivative and medicinal use thereof | CAPN1, OPRM1, CAPN2 | CASP3 1140/4885KMT2A 3923/4885FABP7 432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.